---
title: "hVIVO PLC (AIM:HVO) Director/PDMR Shareholding"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-06-02T06:39:28+00:00"
modified: "2025-06-02T09:02:04+00:00"
date: 2025-06-02
canonical: "https://www.share-talk.com/hvivo-plc-aimhvo-director-pdmr-shareholding/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["Andrew Catchpole", "antiviral", "breast cancer", "Canary Wharf", "Cathal Friel", "CHIMagents", "clinical respiratory drug", "Codagenix", "COVID-19", "Dengue Fever", "Dr Andrew Catchpole", "Dr Chris Chiu", "Gregory Stoloff", "hVIVO", "Imperial College London", "Imutex Ltd", "laboratory", "Malaria", "Open Orphan", "ORPH", "Oxford BioTherapeutics", "pharmaceutical", "quarantine clinic", "Rahim Fandi", "Share Talk", "Stephen Pinkerton", "The Lancet", "Vaccine", "virology", "West Nile Virus", "Yamin 'Mo' Khan", "Zika"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/06/GpNPUTIXIAEh5iU-scaled.webp?fit=900%2C1200&ssl=1"
format: "news"
language: "en-GB"
---

# hVIVO PLC (AIM:HVO) Director/PDMR Shareholding

**Published:** June 2, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** Andrew Catchpole, antiviral, breast cancer, Canary Wharf, Cathal Friel, CHIMagents, clinical respiratory drug, Codagenix, COVID-19, Dengue Fever, Dr Andrew Catchpole, Dr Chris Chiu, Gregory Stoloff, hVIVO, Imperial College London, Imutex Ltd, laboratory, Malaria, Open Orphan, ORPH, Oxford BioTherapeutics, pharmaceutical, quarantine clinic, Rahim Fandi, Share Talk, Stephen Pinkerton, The Lancet, Vaccine, virology, West Nile Virus, Yamin 'Mo' Khan, Zika
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2025/06/GpNPUTIXIAEh5iU-scaled.webp?fit=900%2C1200&ssl=1)

---

**hVIVO plc (AIM: HVO),** a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, [purchased shares in the Company](https://www.voxmarkets.co.uk/rns/announcement/8f3ca7d3-8f30-4b21-9449-f2bfa260dedd/) as detailed below:

|   |   |   |   |   |
| --- | --- | --- | --- | --- |
| Director | No of shares purchased | Purchase Price | Resultant holding | Resultant holding as a % of the issued share capital |
| Yamin ‘Mo’ Khan | 1,100,000 | 8.9 pence | 5,001,603 | 0.73% |
| Stephen Pinkerton | 683,232* | 8.76 pence | 750,596* | 0.11% |
| hVIVO plc | +44 (0)20 7756 1300 |  |  |  |
| Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |  |  |  |  |
|  |  |  |  |  |

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton, wife of Stephen Pinkerton

Commenting, Dr Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “Friday’s trading update clearly raised concerns for our shareholders, but we remain confident in the continued growth of human challenge trials and the overall prospects for hVIVO, and accordingly Stephen and I have increased our shareholdings in the Company to demonstrate our continued confidence in the growth prospects of the Group.

“We have our largest ever sales pipeline, including projects under discussion that would represent some of our biggest ever value contracts for human challenge trials, such as the world’s first ever Phase 3 HCT. We have also successfully targeted a more diversified revenue base and we remain very excited about the growth prospects of our hLAB services as well as our new revenue streams from CRS’s early phase clinical trial services and participant recruitment.”

For further information please contact:

|   |   |
| --- | --- |
| hVIVO plc | +44 (0)20 7756 1300 |
| Yamin ‘Mo’ Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer |  |

![A person taking a selfie in front of a city Description automatically generated](https://i0.wp.com/dw6uz0omxro53.cloudfront.net/3404687/9871ccaa-8a7d-43c8-aae9-caa41bb78ff6.jpg?w=800&ssl=1)

 Notes to Editors

[hVIVO plc](https://hvivo.com/) (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the [hLAB](https://hlabservices.com/) brand.

Through its German subsidiary, [CRS](https://crs-earlyphase.com/), hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, [Venn Life Sciences](https://www.vennlifesciences.com/), offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via [FluCamp](https://flucamp.com/). Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

---

**Original URL:** https://www.share-talk.com/hvivo-plc-aimhvo-director-pdmr-shareholding/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*